Orelabrutinib, Lenalidomide, and Rituximab as Frontline Therapy for Mantle Cell Lymphoma: Results of the Phase II POLARIS Study (ESMO Asia 2026) - Oct 1, 2026 - Abstract #268P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
P2 data • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology
|
|
Zheng Song; Xiaohui Wang; Huilai Zhang
|